Evaxion Biotech A/S (NASDAQ:EVAX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research note published on Thursday, Benzinga reports. HC Wainwright currently has a $14.00 target price on the stock.

Evaxion Biotech A/S Price Performance

Evaxion Biotech A/S stock opened at $3.12 on Thursday. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80. Evaxion Biotech A/S has a one year low of $2.26 and a one year high of $13.61. The company has a market cap of $16.88 million, a P/E ratio of -0.72 and a beta of -0.27. The business has a fifty day moving average of $3.00 and a two-hundred day moving average of $3.31.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.14). The firm had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million. During the same quarter last year, the business earned ($2.10) earnings per share. As a group, analysts predict that Evaxion Biotech A/S will post -0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Armistice Capital LLC lifted its holdings in Evaxion Biotech A/S by 6.8% in the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock valued at $1,137,000 after purchasing an additional 25,000 shares in the last quarter. Invst LLC purchased a new stake in shares of Evaxion Biotech A/S during the 2nd quarter valued at $156,000. Finally, LM Advisors LLC purchased a new position in shares of Evaxion Biotech A/S in the 4th quarter worth $231,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.